GENFLOW BIOSCIENCES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.05 GBX | +1.67% |
|
+12.96% | +114.04% |
| 05-30 | Genflow Biosciences receives 50% of grant for sarcopenia project | AN |
| 05-30 | Genflow Biosciences Secures Grant for Sarcopenia Research Program | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 4.17M 327M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -78.48M | Net income 2023 | -1M -78.48M | EV / Sales 2022 | - |
| Net cash position 2022 | 2.36M 185M | Net cash position 2023 | 684K 53.68M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-5.26
x | P/E ratio 2023 |
-2.56
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.13% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.67% | ||
| 1 week | +12.96% | ||
| 1 month | +48.78% | ||
| 3 months | +106.78% | ||
| 6 months | +76.81% | ||
| Current year | +114.04% |
1 week
2.60
3.41
1 month
1.803.41
Current year
1.323.41
1 year
1.323.90
3 years
1.3213.50
5 years
1.3213.50
10 years
1.3213.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 31/12/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 28/06/22 | |
Tamara Joseph
CHM | Chairman | 61 | 28/06/22 |
| Founder | 66 | 31/12/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 3.05 | +1.67% | 2,766,995 |
| 30/05/24 | 3 | -.--% | 3,411,954 |
| 29/05/24 | 3 | -1.64% | 2,878,247 |
| 28/05/24 | 3.05 | +12.96% | 4,462,394 |
Delayed Quote London S.E., May 31, 2024 at 04:35 pm
More quotes
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
Calendar
26/09/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +114.04% | 13.57M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- GENF Stock